drugset
drugset / Trial / NCT01887587

Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

NCT01887587 ↗

Phase 1 Terminated 5 enrolled Ehab L Atallah
NaSingle-groupOpen-labelTreatment

Summary

This is a phase I study of vincristine, doxorubicin and dexamethasone (modified VXD) plus MLN9708 in adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma, lymphoblastic lymphoma or mixed phenotype acute leukemia.

Timeline

Start
2013-06
Primary completion
2016-02-29
Completion
2016-02-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Ixazomib Unknown 1.5 mg Oral
Subject Ixazomib Unknown 2.3 mg Oral
Subject Ixazomib Unknown 3 mg Oral
Subject Ixazomib Unknown 4 mg Oral
Background Dexamethasone Small molecule 10 mg/m2 Oral
Background Doxorubicin Other / unclassified 60 mg/m2 Intravenous
Background Vincristine Small molecule 1.5 mg/m2 Intravenous

Indications

adult acute lymphoblastic leukemia mixed phenotype acute leukemia